Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521891

SCHEMBL1521891

SCHEMBL1521891

Cc1cc(F)c(NC(=O)Nc2cc(C(C)(C)C)no2)cc1N1Cc2cnc(NCCN(C)C)nc2N(C)C1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNK2 Q07912 9/20 0.46
▸ MAP4K2 Q12851 9/20 0.46
▸ BMX P51813 10/20 0.39
▸ ABL1 P00519 3/20 0.39
▸ BCR P11274 1/20 0.39
▸ RIPK1 Q13546 1/20 0.39
▸ RIPK3 Q9Y572 1/20 0.39
▸ MAPK14 Q16539 2/20 0.38
▸ KDR P35968 2/20 0.38
▸ LCK P06239 1/20 0.38
▸ FES P07332 1/20 0.38
▸ RET P07949 1/20 0.38
▸ PDGFRB P09619 1/20 0.38
▸ KIT P10721 1/20 0.38
▸ FGFR1 P11362 1/20 0.38
▸ SRC P12931 1/20 0.38
▸ PDGFRA P16234 1/20 0.38
▸ FLT1 P17948 1/20 0.38
▸ FGFR3 P22607 1/20 0.38
▸ EPHA3 P29320 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521778 0.95 TNK2 (0.48) TNK2MAP4K2BMXABL1BCR
SCHEMBL1521733 0.89 ABL1 (0.45) TNK2MAP4K2BMXABL1BCR
SCHEMBL1521542 0.86 TNK2 (0.49) TNK2MAP4K2BMXABL1BCR
SCHEMBL1521615 0.84 FGFR4 (0.42) TNK2MAP4K2BMXABL1BCR
SCHEMBL1521665 0.83 ABL1 (0.48) TNK2MAP4K2BMXABL1BCR
SCHEMBL1522011 0.82 NEK7 (0.35) TNK2MAP4K2BMXABL1BCR
SCHEMBL1521858 0.81 BRAF (0.46) TNK2MAP4K2BMXABL1MAPK14
SCHEMBL1521598 0.81 BRAF (0.42) TNK2MAP4K2BMXABL1MAPK14
SCHEMBL4276053 0.79 BRAF (0.39) ABL1MAPK14KDRRETSRC
SCHEMBL1521554 0.79 BRAF (0.48) MAPK14KDRRETNTRK3KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US claimed
EP-2063896-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 — — EP claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US claimed
WO-2008033999-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-03-20 — — WO claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 TNK2 119/4885MAP4K2 22/4885BMX 947/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 TNK2 119/4885MAP4K2 22/4885BMX 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.